Do analysts prefer GOSS or TLSA?

Gossamer Bio presently has a consensus price target of $3.20, suggesting a potential upside of 2,252.94%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, GOSS or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $55.54M 0.57 -$170.37M -$0.79 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is GOSS or TLSA more profitable?

Tiziana Life Sciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% Tiziana Life Sciences N/A N/A N/A

Is GOSS or NGEN more profitable?

NervGen Pharma has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% NervGen Pharma N/A N/A N/A

Do analysts recommend CUE or GOSS?

Gossamer Bio has a consensus target price of $3.20, indicating a potential upside of 2,252.94%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11

Is HUMA or GOSS more profitable?

Gossamer Bio has a net margin of -324.82% compared to Humacyte's net margin of -4,836.06%. Gossamer Bio's return on equity of 0.00% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% Gossamer Bio -324.82% N/A -96.10%

Gossamer Bio (GOSS) Competitors

$0.14 -0.01 (-4.56%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.14 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

GOSS vs. CNTB, TLSA, NGEN, CUE, and HUMA

Should you buy Gossamer Bio stock or one of its competitors? MarketBeat compares Gossamer Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gossamer Bio include Connect Biopharma (CNTB), Tiziana Life Sciences (TLSA), NervGen Pharma (NGEN), Cue Biopharma (CUE), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry.

How does Gossamer Bio compare to Connect Biopharma?

Gossamer Bio (NASDAQ:GOSS) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Connect Biopharma had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 2 mentions for Connect Biopharma and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.87 beat Connect Biopharma's score of 1.73 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Very Positive
Connect Biopharma	Very Positive

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Connect Biopharma has lower revenue, but higher earnings than Gossamer Bio. Connect Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A
Connect Biopharma	$233K	578.30	-$55.48M	-$1.15	N/A

Connect Biopharma has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Connect Biopharma	N/A	-122.29%	-97.07%

Gossamer Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

Gossamer Bio presently has a consensus target price of $3.20, indicating a potential upside of 2,252.94%. Connect Biopharma has a consensus target price of $7.29, indicating a potential upside of 240.45%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Gossamer Bio beats Connect Biopharma on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Tiziana Life Sciences?

Gossamer Bio (NASDAQ:GOSS) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Gossamer Bio and Gossamer Bio both had 1 articles in the media. Gossamer Bio's average media sentiment score of 1.87 equaled Tiziana Life Sciences'average media sentiment score.

Company	Overall Sentiment
Gossamer Bio	Very Positive
Tiziana Life Sciences	Very Positive

Tiziana Life Sciences has lower revenue, but higher earnings than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Tiziana Life Sciences	N/A	N/A	N/A

Gossamer Bio presently has a consensus price target of $3.20, suggesting a potential upside of 2,252.94%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

81.2% of Gossamer Bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.

How does Gossamer Bio compare to NervGen Pharma?

Gossamer Bio (NASDAQ:GOSS) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

NervGen Pharma has lower revenue, but higher earnings than Gossamer Bio. NervGen Pharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, NervGen Pharma had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for NervGen Pharma and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.87 beat NervGen Pharma's score of 0.62 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Very Positive
NervGen Pharma	Positive

81.2% of Gossamer Bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 5.8% of NervGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gossamer Bio currently has a consensus target price of $3.20, suggesting a potential upside of 2,252.94%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Given Gossamer Bio's higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than NervGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

NervGen Pharma has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
NervGen Pharma	N/A	N/A	N/A

Summary

NervGen Pharma beats Gossamer Bio on 7 of the 13 factors compared between the two stocks.

How does Gossamer Bio compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Gossamer Bio has a consensus target price of $3.20, indicating a potential upside of 2,252.94%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Cue Biopharma had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for Cue Biopharma and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.87 beat Cue Biopharma's score of 0.81 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Positive
Gossamer Bio	Very Positive

Cue Biopharma has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Cue Biopharma has a net margin of -59.65% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Gossamer Bio	-324.82%	N/A	-96.10%

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cue Biopharma has higher earnings, but lower revenue than Gossamer Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$32.73M	4.12	-$26.60M	-$5.58	N/A
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A

Summary

Gossamer Bio beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Humacyte had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 2 mentions for Humacyte and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.87 beat Humacyte's score of 0.48 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Neutral
Gossamer Bio	Very Positive

Humacyte presently has a consensus price target of $6.25, indicating a potential upside of 900.32%. Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 2,252.94%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Humacyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Humacyte has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Humacyte has higher earnings, but lower revenue than Gossamer Bio. Humacyte is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.02M	68.81	-$40.83M	-$0.57	N/A
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A

44.7% of Humacyte shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gossamer Bio has a net margin of -324.82% compared to Humacyte's net margin of -4,836.06%. Gossamer Bio's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Gossamer Bio	-324.82%	N/A	-96.10%

Summary

Humacyte and Gossamer Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$33.44M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.17	21.29	27.11	23.64
Price / Sales	0.57	170.12	517.09	89.57
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-0.26	7.88	10.28	6.07
Net Income	-$170.37M	$23.86M	$3.60B	$331.99M
7 Day Performance	-20.14%	-3.82%	-1.27%	-0.63%
1 Month Performance	-17.68%	-2.61%	-0.37%	-2.00%
1 Year Performance	-92.61%	32.79%	18.30%	13.62%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.5757 of 5 stars	$0.14 -4.6%	$3.20 +2,252.9%	-92.4%	$33.44M	$55.54M	N/A	180	Positive News
CNTB Connect Biopharma	4.571 of 5 stars	$2.26 -10.0%	$7.29 +222.4%	-8.9%	$158.04M	$60K	N/A	110	News Coverage
TLSA Tiziana Life Sciences	1.11 of 5 stars	$1.33 +8.1%	N/A	-48.7%	$156.53M	N/A	N/A	8	Positive News Gap Down High Trading Volume
NGEN NervGen Pharma	2.3413 of 5 stars	$1.93 +2.7%	$14.00 +625.4%	N/A	$155.62M	N/A	N/A	N/A	Analyst Forecast High Trading Volume
CUE Cue Biopharma	0.1939 of 5 stars	$30.92 -15.9%	N/A	-96.1%	$154.49M	$27.47M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. CNTB, TLSA, NGEN, CUE, and HUMA

How does Gossamer Bio compare to Connect Biopharma?

Summary

How does Gossamer Bio compare to Tiziana Life Sciences?

Summary

How does Gossamer Bio compare to NervGen Pharma?

Summary

How does Gossamer Bio compare to Cue Biopharma?

Summary

How does Gossamer Bio compare to Humacyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. CNTB, TLSA, NGEN, CUE, and HUMA

How does Gossamer Bio compare to Connect Biopharma?

Does the media refer more to GOSS or CNTB?

Do institutionals and insiders believe in GOSS or CNTB?

Which has higher earnings and valuation, GOSS or CNTB?

Is GOSS or CNTB more profitable?

Which has more volatility and risk, GOSS or CNTB?

Do analysts prefer GOSS or CNTB?

Summary

How does Gossamer Bio compare to Tiziana Life Sciences?

Does the media prefer GOSS or TLSA?

Which has stronger earnings and valuation, GOSS or TLSA?

Which has more volatility & risk, GOSS or TLSA?

Is GOSS or TLSA more profitable?

Do analysts prefer GOSS or TLSA?

Do insiders & institutionals have more ownership in GOSS or TLSA?

Summary

How does Gossamer Bio compare to NervGen Pharma?

Which has better valuation and earnings, GOSS or NGEN?

Does the media favor GOSS or NGEN?

Do institutionals and insiders have more ownership in GOSS or NGEN?

Do analysts rate GOSS or NGEN?

Is GOSS or NGEN more profitable?

Summary

How does Gossamer Bio compare to Cue Biopharma?

Do analysts recommend CUE or GOSS?

Does the media favor CUE or GOSS?

Which has more volatility and risk, CUE or GOSS?

Is CUE or GOSS more profitable?

Do institutionals & insiders believe in CUE or GOSS?

Which has stronger valuation & earnings, CUE or GOSS?

Summary

How does Gossamer Bio compare to Humacyte?

Does the media favor HUMA or GOSS?

Do analysts recommend HUMA or GOSS?

Which has more risk & volatility, HUMA or GOSS?

Which has better earnings and valuation, HUMA or GOSS?

Do institutionals and insiders believe in HUMA or GOSS?

Is HUMA or GOSS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools